Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials).

Jatene T, Biering-Sørensen T, Nochioka K, Mangione FM, Hansen KW, Sørensen R, Jensen JS, Jørgensen PG, Jeger R, Kaiser C, Pfisterer M, Galatius S; BASKET-PROVE Investigators.

Am J Cardiol. 2017 Jan 1;119(1):14-19. doi: 10.1016/j.amjcard.2016.09.013. Epub 2016 Sep 29.

PMID:
27788931
2.

Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study.

Nochioka K, Biering-Sørensen T, Hansen KW, Sørensen R, Pedersen S, Jørgensen PG, Iversen A, Shimokawa H, Jeger R, Kaiser C, Pfisterer M, Galatius S; BASKET-PROVE Investigators.

Eur Heart J Acute Cardiovasc Care. 2017 Dec;6(8):778-786. doi: 10.1177/2048872616649860. Epub 2016 May 10.

PMID:
27166320
3.

Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial.

Vassalli G, Klersy C, De Servi S, Galatius S, Erne P, Eberli F, Rickli H, Hornig B, Bertel O, Bonetti P, Moccetti T, Kaiser C, Pfisterer M, Pedrazzini G; BASKET-PROVE Investigators.

Am Heart J. 2016 Mar;173:1-7. doi: 10.1016/j.ahj.2015.11.007. Epub 2015 Dec 1.

PMID:
26920590
4.

Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial.

Pedersen SH, Pfisterer M, Kaiser C, Jensen JS, Alber H, Rickenbacher P, Sørensen R, Iversen A, Jensen MT, Wadt K, Galatius S; BASKET-PROVE Investigators.

EuroIntervention. 2014 May;10(1):58-64. doi: 10.4244/EIJV10I1A11.

5.

Improved two-year outcomes after drug-eluting versus bare-metal stent implantation in women and men with large coronary arteries: importance of vessel size.

Hansen KW, Kaiser C, Hvelplund A, Soerensen R, Madsen JK, Jensen JS, Pedersen SH, Eberli FR, Erne P, Alber H, Pfisterer M, Galatius S; BASKET PROVE Investigators.

Int J Cardiol. 2013 Oct 25;169(1):29-34. doi: 10.1016/j.ijcard.2013.08.091. Epub 2013 Sep 8.

PMID:
24063913
6.

Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial.

Jensen MT, Kaiser C, Sandsten KE, Alber H, Wanitschek M, Iversen A, Jensen JS, Pedersen S, Soerensen R, Rickli H, Zurek M, Fahrni G, Bertel O, De Servi S, Erne P, Pfisterer M, Galatius S; BASKET-PROVE investigators.

Int J Cardiol. 2013 Oct 9;168(4):3802-6. doi: 10.1016/j.ijcard.2013.06.034. Epub 2013 Jul 11.

PMID:
23849965
7.

Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.

Wanitschek M, Pfisterer M, Hvelplund A, De Servi S, Bertel O, Jeger R, Rickenbacher P, Iversen A, Jensen JS, Galatius S, Kaiser C, Alber H; BASKET-PROVE Investigators.

Int J Cardiol. 2013 Oct 3;168(3):2381-8. doi: 10.1016/j.ijcard.2013.01.257. Epub 2013 Feb 27.

PMID:
23453439
8.

Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.

Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C; BASKET-PROVE Investigators.

Am Heart J. 2008 Apr;155(4):609-14. doi: 10.1016/j.ahj.2007.11.011. Epub 2008 Feb 21.

PMID:
18371466

Supplemental Content

Loading ...
Support Center